XML 64 R51.htm IDEA: XBRL DOCUMENT
v3.25.3

Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024
Research and development expense | $ 607 | $ 1,437 | $ 2,861 | $ 4,533
Amarex Clinical Research LLC [Member] |  |  |  |
Research and development expense | 3 | 157 | 207 | 337
Amarex Clinical Research LLC [Member] | Pancreatic Cancer [Member] |  |  |  |
Research and development expense | 3 | 129 | 199 | 141
Amarex Clinical Research LLC [Member] | Post COVID Conditions [Member] |  |  |  |
Research and development expense |  | 28 | 8 | 196
Jubilant HollisterStier [Member] |  |  |  |
Research and development expense |  |  |  | 1
Sterling Pharma Solutions [Member] |  |  |  |
Research and development expense |  | 133 |  | 262
Erasmus [Member] |  |  |  |
Research and development expense |  |  |  | 79
Azenova Sales International [Member] |  |  |  |
Research and development expense |  | 50 |  | 230
Alcami [Member] |  |  |  |
Research and development expense | 5 |  | 10 | 14
Clinical Studies [Member] |  |  |  |
Research and development expense | 309 | 582 | 1,636 | 1,880
Manufacturing and Engineering [Member] |  |  |  |
Research and development expense | 57 | 306 | 381 | 882
Quality Control [Member] |  |  |  |
Research and development expense | 221 | 398 | 685 | 1,232
Regulatory [Member] |  |  |  |
Research and development expense | $ 20 | $ 151 | $ 159 | $ 539

X
- Definition Amount of other research and development expense. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=AIMI_AmarexClinicalResearchLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIMI_PancreaticCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=AIMI_PostCOVIDConditionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_JubilantHollisterStierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_SterlingPharmaSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_ErasmusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_AzenovaSalesInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=AIMI_AlcamiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIMI_ClinicalStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIMI_ManufacturingAndEngineeringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIMI_QualityControlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=AIMI_RegulatoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |